3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
23
Terminated
5
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
15
Gastrointestinal
7
Genitourinary
6
Endocrine
6
Tumor-Agnostic
4
Head & Neck
3
Sarcoma
2
Other solid neoplasm
2
Other hematologic neoplasm
2
NET
2
Thoracic
1
Other neoplasm
1
Lymphoid
1
Gynecologic
1
Dermatologic
1
CNS
1
Conditions
Gastrointestinal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Carboplatin
132
Cisplatin
129
Pemetrexed
114
Docetaxel
81
Drug Therapy
62
Gefitinib
57
anlotinib
55
Gemcitabine
55
Erlotinib Hydrochloride
55
Radiotherapy
48
Bevacizumab
48
pembrolizumab
47
Paclitaxel
47
Etoposide
44
apatinib
42
icotinib
41
camrelizumab
39
osimertinib
36
Nivolumab
33
Vinorelbine
31
Radiosurgery
30
sintilimab
29
durvalumab
25
aumolertinib
25
endostar protein
24
atezolizumab
22
Endostatins
22
toripalimab
19
Blood Specimen Collection
19
tislelizumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Everolimus
×
Thoracic
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled